Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial.

Clinical and experimental gastroenterology

Eleje GU, Ogbunugafor HA, Emegoakor CD, Okoye EI, Ezejiofor OI, Chukwurah SN, Ikechebelu JI, Nchinda GW, Ugochukwu CG, Nnaji-Ihedinmah LI, Okoye FBC, Eneh FU, Onwukamuche ME, Esimone CO.
PMID: 30679917
Clin Exp Gastroenterol. 2019 Jan 15;12:21-30. doi: 10.2147/CEG.S178179. eCollection 2019.

BACKGROUND: To our knowledge, there is no prior randomized study on the utility of Syferol-IHP (blend of virgin coconut oil and AIM: This study determined the efficacy and safety of Syferol-IHP as adjunct to conventional triple therapy for the...

Cite
Eleje GU, Ogbunugafor HA, Emegoakor CD, et al. Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial. Clin Exp Gastroenterol. 2019;12:21-30doi: 10.2147/CEG.S178179.
Eleje, G. U., Ogbunugafor, H. A., Emegoakor, C. D., Okoye, E. I., Ezejiofor, O. I., Chukwurah, S. N., Ikechebelu, J. I., Nchinda, G. W., Ugochukwu, C. G., Nnaji-Ihedinmah, L. I., Okoye, F. B. C., Eneh, F. U., Onwukamuche, M. E., & Esimone, C. O. (2019). Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial. Clinical and experimental gastroenterology, 1221-30. https://doi.org/10.2147/CEG.S178179
Eleje, George Uchenna, et al. "Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial." Clinical and experimental gastroenterology vol. 12 (2019): 21-30. doi: https://doi.org/10.2147/CEG.S178179
Eleje GU, Ogbunugafor HA, Emegoakor CD, Okoye EI, Ezejiofor OI, Chukwurah SN, Ikechebelu JI, Nchinda GW, Ugochukwu CG, Nnaji-Ihedinmah LI, Okoye FBC, Eneh FU, Onwukamuche ME, Esimone CO. Efficacy and safety of Syferol-IHP for the treatment of peptic ulcer disease: a pilot, double-blind randomized trial. Clin Exp Gastroenterol. 2019 Jan 15;12:21-30. doi: 10.2147/CEG.S178179. eCollection 2019. PMID: 30679917; PMCID: PMC6338118.
Copy Download .nbib Format: NLM
Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and .

Journal of medicinal chemistry

Horatscheck A, Andrijevic A, Nchinda AT, Le Manach C, Paquet T, Khonde LP, Dam J, Pawar K, Taylor D, Lawrence N, Brunschwig C, Gibhard L, Njoroge M, Reader J, van der Watt M, Wicht K, de Sousa ACC, Okombo J, Maepa K, Egan TJ, Birkholtz LM, Basarab GS, Wittlin S, Fish PV, Street LJ, Duffy J, Chibale K.
PMID: 33508187
J Med Chem. 2021 Feb 11;64(3):1762. doi: 10.1021/acs.jmedchem.1c00064. Epub 2021 Jan 28.

No abstract available.

Cite
Horatscheck A, Andrijevic A, Nchinda AT, et al. Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and . J Med Chem. 2021;64(3):1762doi: 10.1021/acs.jmedchem.1c00064.
Horatscheck, A., Andrijevic, A., Nchinda, A. T., Le Manach, C., Paquet, T., Khonde, L. P., Dam, J., Pawar, K., Taylor, D., Lawrence, N., Brunschwig, C., Gibhard, L., Njoroge, M., Reader, J., van der Watt, M., Wicht, K., de Sousa, A. C. C., Okombo, J., Maepa, K., Egan, T. J., Birkholtz, L. M., Basarab, G. S., Wittlin, S., Fish, P. V., Street, L. J., Duffy, J., & Chibale, K. (2021). Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and . Journal of medicinal chemistry, 64(3), 1762. https://doi.org/10.1021/acs.jmedchem.1c00064
Horatscheck, André, et al. "Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and ." Journal of medicinal chemistry vol. 64,3 (2021): 1762. doi: https://doi.org/10.1021/acs.jmedchem.1c00064
Horatscheck A, Andrijevic A, Nchinda AT, Le Manach C, Paquet T, Khonde LP, Dam J, Pawar K, Taylor D, Lawrence N, Brunschwig C, Gibhard L, Njoroge M, Reader J, van der Watt M, Wicht K, de Sousa ACC, Okombo J, Maepa K, Egan TJ, Birkholtz LM, Basarab GS, Wittlin S, Fish PV, Street LJ, Duffy J, Chibale K. Correction to "Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and . J Med Chem. 2021 Feb 11;64(3):1762. doi: 10.1021/acs.jmedchem.1c00064. Epub 2021 Jan 28. PMID: 33508187.
Copy Download .nbib Format: NLM
Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon.

Scientific reports

Sagnia B, Kiazyk S, Meyers AFA, Plews M, Diallo TO, Sosso SM, Ambada G, Kamgaing R, Nji N, Sandstrom P, Ball BT, Nchinda G, Ndjolo A.
PMID: 34078982
Sci Rep. 2021 Jun 02;11(1):11536. doi: 10.1038/s41598-021-91015-7.

Participation in an EQA program is critical to the quality assurance process. Reliable and precise CD4 T-cells enumeration are essential to improve the clinical management of patients by evaluating the disease progression and by monitoring the effectiveness of ART...

Cite
Sagnia B, Kiazyk S, Meyers AFA, et al. Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon. Sci Rep. 2021;11(1):11536doi: 10.1038/s41598-021-91015-7.
Sagnia, B., Kiazyk, S., Meyers, A. F. A., Plews, M., Diallo, T. O., Sosso, S. M., Ambada, G., Kamgaing, R., Nji, N., Sandstrom, P., Ball, B. T., Nchinda, G., & Ndjolo, A. (2021). Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon. Scientific reports, 11(1), 11536. https://doi.org/10.1038/s41598-021-91015-7
Sagnia, Bertrand, et al. "Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon." Scientific reports vol. 11,1 (2021): 11536. doi: https://doi.org/10.1038/s41598-021-91015-7
Sagnia B, Kiazyk S, Meyers AFA, Plews M, Diallo TO, Sosso SM, Ambada G, Kamgaing R, Nji N, Sandstrom P, Ball BT, Nchinda G, Ndjolo A. Evaluation of a collaborative model for successful implementation of a National CD4 enumeration EQA program in Cameroon. Sci Rep. 2021 Jun 02;11(1):11536. doi: 10.1038/s41598-021-91015-7. PMID: 34078982; PMCID: PMC8172912.
Copy Download .nbib Format: NLM
Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Antimicrobial agents and chemotherapy

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.
PMID: 30355750
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01941-18. Print 2018 Nov.

No abstract available.

Cite
Brunschwig C, Lawrence N, Taylor D, et al. Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria". Antimicrob Agents Chemother. 2018;62(11)doi: 10.1128/AAC.01941-18.
Brunschwig, C., Lawrence, N., Taylor, D., Abay, E., Njoroge, M., Basarab, G. S., Le Manach, C., Paquet, T., Gonzàlez Cabrera, D., Nchinda, A. T., de Kock, C., Wiesner, L., Denti, P., Waterson, D., Blasco, B., Leroy, D., Witty, M. J., Donini, C., Duffy, J., Wittlin, S., White, K. L., Charman, S. A., Jiménez-Díaz, M. B., Angulo-Barturen, I., Herreros, E., Gamo, F. J., Rochford, R., Mancama, D., Coetzer, T. L., van der Watt, M. E., Reader, J., Birkholtz, L. M., Marsh, K. C., Solapure, S. M., Burke, J. E., McPhail, J. A., Vanaerschot, M., Fidock, D. A., Fish, P. V., Siegl, P., Smith, D. A., Wirjanata, G., Noviyanti, R., Price, R. N., Marfurt, J., Silue, K. D., Street, L. J., & Chibale, K. (2018). Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria". Antimicrobial agents and chemotherapy, 62(11), . https://doi.org/10.1128/AAC.01941-18
Brunschwig, Christel, et al. "Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria"." Antimicrobial agents and chemotherapy vol. 62,11 (2018). doi: https://doi.org/10.1128/AAC.01941-18
Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K. Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria". Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01941-18. Print 2018 Nov. PMID: 30355750; PMCID: PMC6201132.
Copy Download .nbib Format: NLM
Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment.

ACS omega

Mueller R, Reddy V, Nchinda AT, Mebrahtu F, Taylor D, Lawrence N, Tanner L, Barnabe M, Eyermann CJ, Zou B, Kondreddi RR, Lakshminarayana SB, Rottmann M, Street LJ, Chibale K.
PMID: 32258933
ACS Omega. 2020 Mar 17;5(12):6967-6982. doi: 10.1021/acsomega.0c00327. eCollection 2020 Mar 31.

A phenotypic whole cell high-throughput screen against the asexual blood and liver stages of the malaria parasite identified a benzimidazole chemical series. Among the hits were the antiemetic benzimidazole drug Lerisetron

Cite
Mueller R, Reddy V, Nchinda AT, et al. Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ACS Omega. 2020;5(12):6967-6982doi: 10.1021/acsomega.0c00327.
Mueller, R., Reddy, V., Nchinda, A. T., Mebrahtu, F., Taylor, D., Lawrence, N., Tanner, L., Barnabe, M., Eyermann, C. J., Zou, B., Kondreddi, R. R., Lakshminarayana, S. B., Rottmann, M., Street, L. J., & Chibale, K. (2020). Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ACS omega, 5(12), 6967-6982. https://doi.org/10.1021/acsomega.0c00327
Mueller, Rudolf, et al. "Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment." ACS omega vol. 5,12 (2020): 6967-6982. doi: https://doi.org/10.1021/acsomega.0c00327
Mueller R, Reddy V, Nchinda AT, Mebrahtu F, Taylor D, Lawrence N, Tanner L, Barnabe M, Eyermann CJ, Zou B, Kondreddi RR, Lakshminarayana SB, Rottmann M, Street LJ, Chibale K. Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ACS Omega. 2020 Mar 17;5(12):6967-6982. doi: 10.1021/acsomega.0c00327. eCollection 2020 Mar 31. PMID: 32258933; PMCID: PMC7114883.
Copy Download .nbib Format: NLM
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Antimicrobial agents and chemotherapy

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.
PMID: 29941635
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00012-18. Print 2018 Sep.

The 2-aminopyridine MMV048 was the first drug candidate inhibiting

Cite
Brunschwig C, Lawrence N, Taylor D, et al. UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrob Agents Chemother. 2018;62(9)doi: 10.1128/AAC.00012-18.
Brunschwig, C., Lawrence, N., Taylor, D., Abay, E., Njoroge, M., Basarab, G. S., Le Manach, C., Paquet, T., Cabrera, D. G., Nchinda, A. T., de Kock, C., Wiesner, L., Denti, P., Waterson, D., Blasco, B., Leroy, D., Witty, M. J., Donini, C., Duffy, J., Wittlin, S., White, K. L., Charman, S. A., Jiménez-Díaz, M. B., Angulo-Barturen, I., Herreros, E., Gamo, F. J., Rochford, R., Mancama, D., Coetzer, T. L., van der Watt, M. E., Reader, J., Birkholtz, L. M., Marsh, K. C., Solapure, S. M., Burke, J. E., McPhail, J. A., Vanaerschot, M., Fidock, D. A., Fish, P. V., Siegl, P., Smith, D. A., Wirjanata, G., Noviyanti, R., Price, R. N., Marfurt, J., Silue, K. D., Street, L. J., & Chibale, K. (2018). UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial agents and chemotherapy, 62(9), . https://doi.org/10.1128/AAC.00012-18
Brunschwig, Christel, et al. "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria." Antimicrobial agents and chemotherapy vol. 62,9 (2018). doi: https://doi.org/10.1128/AAC.00012-18
Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K. UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00012-18. Print 2018 Sep. PMID: 29941635; PMCID: PMC6125526.
Copy Download .nbib Format: NLM
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in .

Journal of medicinal chemistry

Khonde LP, Müller R, Boyle GA, Reddy V, Nchinda AT, Eyermann CJ, Fienberg S, Singh V, Myrick A, Abay E, Njoroge M, Lawrence N, Su Q, Myers TG, Boshoff HIM, Barry CE, Sirgel FA, van Helden PD, Massoudi LM, Robertson GT, Lenaerts AJ, Basarab GS, Ghorpade SR, Chibale K.
PMID: 34414766
J Med Chem. 2021 Sep 09;64(17):12790-12807. doi: 10.1021/acs.jmedchem.1c00837. Epub 2021 Aug 20.

Phenotypic whole cell high-throughput screening of a ∼150,000 diverse set of compounds against

Cite
Khonde LP, Müller R, Boyle GA, et al. 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in . J Med Chem. 2021;64(17):12790-12807doi: 10.1021/acs.jmedchem.1c00837.
Khonde, L. P., Müller, R., Boyle, G. A., Reddy, V., Nchinda, A. T., Eyermann, C. J., Fienberg, S., Singh, V., Myrick, A., Abay, E., Njoroge, M., Lawrence, N., Su, Q., Myers, T. G., Boshoff, H. I. M., Barry, C. E., Sirgel, F. A., van Helden, P. D., Massoudi, L. M., Robertson, G. T., Lenaerts, A. J., Basarab, G. S., Ghorpade, S. R., & Chibale, K. (2021). 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in . Journal of medicinal chemistry, 64(17), 12790-12807. https://doi.org/10.1021/acs.jmedchem.1c00837
Khonde, Lutete Peguy, et al. "1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in ." Journal of medicinal chemistry vol. 64,17 (2021): 12790-12807. doi: https://doi.org/10.1021/acs.jmedchem.1c00837
Khonde LP, Müller R, Boyle GA, Reddy V, Nchinda AT, Eyermann CJ, Fienberg S, Singh V, Myrick A, Abay E, Njoroge M, Lawrence N, Su Q, Myers TG, Boshoff HIM, Barry CE, Sirgel FA, van Helden PD, Massoudi LM, Robertson GT, Lenaerts AJ, Basarab GS, Ghorpade SR, Chibale K. 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in . J Med Chem. 2021 Sep 09;64(17):12790-12807. doi: 10.1021/acs.jmedchem.1c00837. Epub 2021 Aug 20. PMID: 34414766.
Copy Download .nbib Format: NLM
Global Assessment of Dengue Virus-Specific CD4.

Frontiers in immunology

Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, Balmaseda A, Silveira CGT, Maestri A, Costa PR, Durbin AP, Diehl SA, Phillips E, Mallal S, De Silva AD, Nchinda G, Nkenfou C, Collins MH, de Silva AM, Lim MQ, Macary PA, Tatullo F, Solomon T, Satchidanandam V, Desai A, Ravi V, Coloma J, Turtle L, Rivino L, Kallas EG, Peters B, Harris E, Sette A, Weiskopf D.
PMID: 29081779
Front Immunol. 2017 Oct 13;8:1309. doi: 10.3389/fimmu.2017.01309. eCollection 2017.

BACKGROUND: Dengue is a major public health problem worldwide. Assessment of adaptive immunity is important to understanding immunopathology and to define correlates of protection against dengue virus (DENV). To enable global assessment of CD4METHODS: HLA class II epitopes in...

Cite
Grifoni A, Angelo MA, Lopez B, et al. Global Assessment of Dengue Virus-Specific CD4. Front Immunol. 2017;8:1309doi: 10.3389/fimmu.2017.01309.
Grifoni, A., Angelo, M. A., Lopez, B., O'Rourke, P. H., Sidney, J., Cerpas, C., Balmaseda, A., Silveira, C. G. T., Maestri, A., Costa, P. R., Durbin, A. P., Diehl, S. A., Phillips, E., Mallal, S., De Silva, A. D., Nchinda, G., Nkenfou, C., Collins, M. H., de Silva, A. M., Lim, M. Q., Macary, P. A., Tatullo, F., Solomon, T., Satchidanandam, V., Desai, A., Ravi, V., Coloma, J., Turtle, L., Rivino, L., Kallas, E. G., Peters, B., Harris, E., Sette, A., & Weiskopf, D. (2017). Global Assessment of Dengue Virus-Specific CD4. Frontiers in immunology, 81309. https://doi.org/10.3389/fimmu.2017.01309
Grifoni, Alba, et al. "Global Assessment of Dengue Virus-Specific CD4." Frontiers in immunology vol. 8 (2017): 1309. doi: https://doi.org/10.3389/fimmu.2017.01309
Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, Balmaseda A, Silveira CGT, Maestri A, Costa PR, Durbin AP, Diehl SA, Phillips E, Mallal S, De Silva AD, Nchinda G, Nkenfou C, Collins MH, de Silva AM, Lim MQ, Macary PA, Tatullo F, Solomon T, Satchidanandam V, Desai A, Ravi V, Coloma J, Turtle L, Rivino L, Kallas EG, Peters B, Harris E, Sette A, Weiskopf D. Global Assessment of Dengue Virus-Specific CD4. Front Immunol. 2017 Oct 13;8:1309. doi: 10.3389/fimmu.2017.01309. eCollection 2017. PMID: 29081779; PMCID: PMC5646259.
Copy Download .nbib Format: NLM
The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes.

Biomedicine hub

Sake CS, Ngu L, Ambada G, Chedjou JP, Nji N, Tchadji JC, Lissom A, Tchouangueu TF, Djukouo L, Njambe G, Garcia R, Gutierrez A, Bopda Waffo A, Park CG, Mbacham W, Etoa FX, Nchinda GW.
PMID: 31988903
Biomed Hub. 2017 Apr 21;2(1):1-13. doi: 10.1159/000467386. eCollection 2017.

BACKGROUND: In sub-Saharan Africa, intense perennial METHOD: Magnetically sorted NK cells from antiretroviral naïve HIV-1-infected people were tested for their ability to respond to iRBC following in vitro coculture. NK cell IFN-γ production after coculture was measured through multiparametric...

Cite
Sake CS, Ngu L, Ambada G, et al. The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes. Biomed Hub. 2017;2(1):1-13doi: 10.1159/000467386.
Sake, C. S., Ngu, L., Ambada, G., Chedjou, J. P., Nji, N., Tchadji, J. C., Lissom, A., Tchouangueu, T. F., Djukouo, L., Njambe, G., Garcia, R., Gutierrez, A., Bopda Waffo, A., Park, C. G., Mbacham, W., Etoa, F. X., & Nchinda, G. W. (2017). The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes. Biomedicine hub, 2(1), 1-13. https://doi.org/10.1159/000467386
Sake, Carole Stéphanie, et al. "The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes." Biomedicine hub vol. 2,1 (2017): 1-13. doi: https://doi.org/10.1159/000467386
Sake CS, Ngu L, Ambada G, Chedjou JP, Nji N, Tchadji JC, Lissom A, Tchouangueu TF, Djukouo L, Njambe G, Garcia R, Gutierrez A, Bopda Waffo A, Park CG, Mbacham W, Etoa FX, Nchinda GW. The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes. Biomed Hub. 2017 Apr 21;2(1):1-13. doi: 10.1159/000467386. eCollection 2017. PMID: 31988903; PMCID: PMC6945957.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries